Navigation Links
Taste Receptors in the Gut Identified as New Target for Satiety and Glucose Regulation
Date:11/15/2013

SAN DIEGO, Nov. 15, 2013 /PRNewswire/ -- NaZura BioHealth today announced clinical study results indicating that activation of taste receptors in the lower gut can amplify the release of hormones involved in satiety and glucose regulation.  In an oral presentation to be made today at the Obesity Society's Annual Scientific Meeting, principal investigator Steven R. Smith, MD will describe how NaZura's proprietary Gut Sensory Modulation (GSM) technology can be used to intensify the body's natural, food-driven signals.

Delivering formulations of GRAS (Generally Recognized As Safe) dietary ingredients and FDA-approved food additives to the lower gut activates chemosensory sweet, umami and bitter receptors on enteroendocrine cells. These cells release a number of peptides including peptide YY (PYY), which signals satiety to the brain, and glucagon-like peptide-1 (GLP-1), which plays an important role in glucose regulation. The activation of taste receptors with non-nutritive agonists in effect stimulates the enteroendocrine cells to react as though a greater caloric load had been consumed. In short-term studies, NaZura has shown that formulations of sweet, umami and bitter agonists increased the body's food-driven production of PYY and GLP-1 twofold compared to placebo under various meal conditions.

"NaZura BioHealth has broken new ground with this concept of localized delivery of active compounds to the enteroendocrine cells with the goal of improving weight management and glucose control  " said Alain D. Baron, MD, president and chief executive officer of NaZura BioHealth. "As we're hearing at this week's Obesity Society meeting there remains a significant need for safe solutions to help people manage their weight."

NaZura BioHealth Poster at Obesity Society Annual Scientific Meeting

Activation of Intestinal Taste Receptors Augmented Oral Glucose Stimulated GLP-1 and PYY in Healthy Humans

  • Date and Time: Friday, November 15, 2013, 1:30 p.m. to 3:00 p.m. ET
  • Presenter: Steven R. Smith, MD, Director, Florida Hospital–Sanford-Burnham Translational Research Institute for Metabolism and Diabetes; Professor, Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute; and Chief Scientific Officer, Florida Hospital Research Services.
  • Abstract ID, Category:  T-60-OR, Oral Abstracts Track 3 – Appetite

Based on the GSM findings to date, NaZura is currently conducting a randomized, placebo-controlled, double-blind weight loss study in 240 overweight and moderately obese subjects.

About NaZura BioHealth  
NaZura BioHealth is developing consumer healthcare products based on its proprietary Gut Sensory Modulation (GSM) technology. GSMs are delivered to the lower gut where they intensify the body's natural food-driven signals that trigger a sense of fullness and facilitate glucose regulation. NaZura's lead product is Lovidia™, a dietary supplement for weight management targeted to the consumer health market.   For more information, visit www.NaZuraBio.com.

Media Contacts:
Martin Brown, NaZura BioHealth
Senior Vice President, Finance and Operations
(858) 876-1814 ext. 103
marty.brown@nazurabio.com

Pam Lord
Canale Communications
619-849-6003
pam@canalecomm.com


'/>"/>
SOURCE NaZura BioHealth
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
2. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
3. mHealth Identified as Critical Strategy in Medication Adherence Programs
4. Cord Blood Stem Cells Stored at No Cost to Families with an Identified Medical Need Provide Therapeutic Options
5. Target for potent first-strike influenza drugs identified
6. Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
7. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
8. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Medbox Targets Newly Emerging $1.3 Billion Canadian Medical Marijuana Market
10. Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases
11. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):